Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Fmr LLC

FMR LLC lessened its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 0.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,785,284 shares of the company's stock after selling 16,654 shares during the period. FMR LLC owned 5.08% of Vera Therapeutics worth $123,110,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Algert Global LLC boosted its position in shares of Vera Therapeutics by 34.3% in the third quarter. Algert Global LLC now owns 23,164 shares of the company's stock worth $1,024,000 after purchasing an additional 5,910 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Vera Therapeutics by 3.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 361,805 shares of the company's stock valued at $15,992,000 after buying an additional 10,717 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Vera Therapeutics in the 3rd quarter worth $475,000. Jennison Associates LLC increased its stake in Vera Therapeutics by 1.3% in the 3rd quarter. Jennison Associates LLC now owns 447,098 shares of the company's stock worth $19,762,000 after buying an additional 5,936 shares in the last quarter. Finally, First Turn Management LLC raised its holdings in Vera Therapeutics by 53.3% during the third quarter. First Turn Management LLC now owns 326,494 shares of the company's stock valued at $14,431,000 after acquiring an additional 113,550 shares during the period. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Trading Down 2.7 %

NASDAQ VERA traded down $1.35 during trading hours on Thursday, hitting $48.11. 377,806 shares of the company were exchanged, compared to its average volume of 888,420. Vera Therapeutics, Inc. has a 52 week low of $13.09 and a 52 week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average price of $44.46 and a 200 day moving average price of $39.93. The stock has a market cap of $3.05 billion, a PE ratio of -18.43 and a beta of 1.08.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.21). Analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In related news, Director Beth C. Seidenberg sold 1,177 shares of the firm's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $42.01, for a total value of $49,445.77. Following the transaction, the director now owns 160,376 shares of the company's stock, valued at $6,737,395.76. This trade represents a 0.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the sale, the chief executive officer now owns 307,972 shares of the company's stock, valued at $11,548,950. The trade was a 4.83 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 89,927 shares of company stock worth $3,800,796. Insiders own 21.70% of the company's stock.

Wall Street Analysts Forecast Growth

VERA has been the subject of several research analyst reports. Guggenheim increased their target price on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a research report on Monday, October 28th. Wedbush upped their price target on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. Scotiabank assumed coverage on shares of Vera Therapeutics in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $60.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $107.00 target price on shares of Vera Therapeutics in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $59.22.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.